We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

First-in-Human Study With GNbAC1 in Healthy Volunteers

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 3, 2012
Last Update Posted: December 5, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GeNeuro Innovation SAS
The purpose of this study is to assess the safety and tolerability of single ascending doses of GNbAC1 in healthy male subjects.

Condition Intervention Phase
Multiple Sclerosis Biological: GNbAC1 Biological: GNbAC1 placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Placebo-Controlled First-in-Human Study With GNbAC1

Resource links provided by NLM:

Further study details as provided by GeNeuro Innovation SAS:

Primary Outcome Measures:
  • number of reported adverse events for healthy male subjects receiving single ascending doses of GNbAC1. [ Time Frame: 64 days ]
    the number of adverse events along with the results of physical examinations, ECG and clinical laboratory tests will be used to determine the safety profile of GNbAC1.

Secondary Outcome Measures:
  • pharmacokinetics (PK) characteristics following administration of single ascending doses of GNbAC1 in healthy male subjects [ Time Frame: 64 days ]
    the following parameters will be determined: serum concentrations of GNbAC1 and the derived PK parameters AUC0-inf, AUC0-tlast, %AUC, Cmax, tmax, t1/2, λz, CL, Vss, Vz, MRT.

  • immunogenicity of GNbAC1 [ Time Frame: 64 days ]

Enrollment: 33
Study Start Date: July 2011
Study Completion Date: August 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GNbAC1
Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
Biological: GNbAC1
Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
Placebo Comparator: GNbAC1 placebo
Single dose intravenous (IV) GNbAC1 placebo
Biological: GNbAC1 placebo
Single dose intravenous (IV) GNbAC1 placebo

Detailed Description:
Scientific research has shown that the expression of genes of a virus which is integrated in the Human genetic material, the Multiple Sclerosis associated RetroVirus (MSRV) could play a critical role in the causation of multiple sclerosis. GNbAC1 is an experimental medication, which neutralizes (i.e. inactivates) a protein of MSRV that might contribute to the development or deterioration of multiple sclerosis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male healthy subjects, 18-55 years of age and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram and laboratory tests at Screening and confirmed at baseline.
  • Clinically acceptable for the purposes of the study sitting blood pressure and pulse rate, i.e.: BP: 100 - 150 mm Hg systolic, 50 - 95 mm Hg diastolic and pulse rate: 45 - 100 bpm. Blood pressure and pulse will be measured after 3 minutes resting in a sitting position.
  • Body mass index between 18.5 and 30.0 kg/m2 and body weight in the 50 - 95 kg range.
  • No need for regular concomitant medication
  • Subjects with partners of childbearing potential have to use adequate contraception during, and for at least the four weeks after administration of study medication. Adequate contraception is defined as usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to Screening, of a stable regimen of any form of hormonal contraception or an intra-uterine device. Use of abstinence alone is not considered adequate. Use of a barrier method alone is considered adequate only if the subject was vasectomized at least six months prior to Screening.
  • Ability to communicate well with the investigator and comply with the requirements of the entire study.
  • The subject has given written consent to participate in the study.

Exclusion Criteria:

  • History of serious adverse reactions or hypersensitivity to any drug.
  • Presence or history of any allergy requiring acute or chronic treatment (seasonal allergic rhinitis which requires no treatment may be tolerated).
  • Abnormal physical findings of clinical significance at the Screening or baseline examination which would interfere with the objectives of the study.
  • Need of any prescription medication within 30 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug or anticipated need for any concomitant medication during the study.
  • Participation in a clinical trial during the previous 4 weeks, i.e. from completion of the previous trial to the planned first administration of the current trial.
  • Loss of 500 mL blood or more during the 3 month period before the screening visit of the study, e.g. as a donor.
  • Existence of any surgical or medical condition which might relevantly interfere with the subject safety, the distribution, metabolism or excretion of the drug or the study assessments, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
  • Symptoms of a significant (upon Investigator's medical judgment) somatic or mental illness in the two week period preceding drug administration.
  • History or clinical evidence of significant cardiovascular, respiratory, renal, hepatic,gastrointestinal, hematological, neurologic or other disease.
  • History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.
  • Positive results from the HIV serology.
  • Positive for MSRV env by RNA PCR
  • Clinically significant abnormal laboratory values (as determined by the Principal Investigator in consultation with the sponsor) at the Screening or baseline evaluation.
  • History of serious mental disorders.
  • History of alcohol or drug abuse in the last 3 years.
  • Heavy smokers, i.e. more than 10 cigarettes per day and/or unwillingness to refrain from smoking during the entire in-house period.
  • Positive results of the drug Screening.
  • Need for a vaccination from Screening to End of Study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01699555

Sponsors and Collaborators
GeNeuro Innovation SAS
Principal Investigator: Thierry Kamtchoua, M.D Covance Clinical Research Unit AG
  More Information

Responsible Party: GeNeuro Innovation SAS
ClinicalTrials.gov Identifier: NCT01699555     History of Changes
Other Study ID Numbers: GNC-001
First Submitted: September 27, 2012
First Posted: October 3, 2012
Last Update Posted: December 5, 2012
Last Verified: December 2012

Keywords provided by GeNeuro Innovation SAS:
Multiple sclerosis
Monoclonal antibody
Multiple Sclerosis Associated Retrovirus (MSRV)

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases